A Phase 2 interventional study of ALXN2220 in Amyloid Transthyretin Cardiomyopathy, sponsored by Neurimmune AG. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Neurimmune AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyloidosis with a site in France — 17 open to participants now, 22 under way, 8 of them phase 3. Amyloidosis · France.
Among the 56 studies in Amyloidosis with a site in France, this one is the 42nd largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 4 of the 21 other live ones, and was the 52nd registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →17 of the 56 studies in Amyloidosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
Alnylam Pharmaceuticals · Sites in France, United States, Argentina and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in France, United States, Argentina and 33 more countries
Ages 18–85
Idoven 1903 S.L. · Sites in France, United States, Germany and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25
First in 2001; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 145 across the 48 interventional studies, 601 across the 8 observational. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 56 have an industry lead sponsor. The 10 most frequent:
Neurimmune AG is the lead sponsor of 2 studies on the registry; none are open to participants now.
Neurimmune AG has 2 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyloidosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06978660Idoven 1903 S.L.Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis | 2026-12 |
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
| NCT07721350Hospices Civils de LyonProspective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System | 2027-05 |
| NCT07549841Nantes University HospitalExploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyloidosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
This is a Phase 2, single arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in the patient population of previous participants in Study NI006-101.
The study will also explore changes in cardiac structure and function, and clinical function of this dosing regimen, as well as changes in cardiac amyloid load, structure and function during the treatment-pause since conclusion of Study NI006-101. The study consists of a Screening Period and a 48 week Active Treatment Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ALXN2220 via intravenous (IV) infusion during the Active Treatment Period
Drug: ALXN2220
Participants will receive ALXN2220 via IV infusion.
Change from Baseline to Week 48 in ECV measured by cMRI
Time frame: Baseline, Week 48
Change from Baseline to Week 48 in Heart Retention/Whole Body Retention measured by scintigraphy
Time frame: Baseline, Week 48
Incidence of TEAEs, including serious TEAEs
Time frame: From Baseline up to Week 48
ALXN2220 serum concentrations
Time frame: From Baseline up to Week 48
Incidence of Anti-Drug Antibodies
Time frame: From Baseline up to Week 48
Plan to share: Yes — Neurimmune has a public commitment to allow requests for study data and will be supplying protocol, results and plain language summaries.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Oct 2026, 14 months after the start.
Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cliramitug
Neurimmune AG